One of the University's most successful spin-out companies has moved to new premises in the West of Scotland Science Park as part of an expansion programme.

MD Biosciences Inflammations Discovery Services (MDBIDS) was created in 2005 and has assembled a specialised range of products and services to facilitate drug discovery for inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.

Despite the current challenging economic climate, MD Biosciences has strengthened and expanded its product offering in recent months and the move to new premises from the original housing in the University’s incubator facilities signifies the company’s aspiring hopes for the future.  With specialised laboratories in the USA, Israel and the newly equipped laboratory in Glasgow, MD Biosciences are increasing their capacity for in vitro services and product development to increase product offering.

At a launch event at the new premises, Eddie Moradian, President of MD Biosciences thanked the growing Glasgow team for their continued hard-work and dedication for the success of MDBIDS over the past five years. He also thanked the University’s continued support to the growing company.

The launch was supported the by the University’s Innovation Network programme, which works closely with companies to increase their competitiveness through collaboration including feasibility studies and new technology licensing. The University’s First Step Awards offer financial support of up to £5k per project to help create long-term collaborations between SMEs and the University’s academics and researchers.

For more information on MD Biosciences, visit http://www.mdbiosciences.com/

For more information on the Innovation Network or how to access £5K funding to work with an SME, visit www.glasgow.ac.uk/workwithus

First published: 5 November 2009

<< November